In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roivant acquires a Glaxo Alzheimer’s compound

Executive Summary

Roivant Sciences Ltd., via its wholly owned subsidiary Roivant Neurosciences Ltd., acquired GlaxoSmithKline PLC's Phase II SB742457 (GSK742457), a selective 5-HT6 antagonist for cognitive and other functional defects in neurological diseases. NOTES: Roivant Neurosciences is now called Axovant Sciences Ltd. and SB742457 was renamed RVT101.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Product Purchase
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies